Balyasny Asset Management L.P. Invests $870,000 in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Balyasny Asset Management L.P. purchased a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 187,030 shares of the company's stock, valued at approximately $870,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. National Bank of Canada FI grew its position in GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after acquiring an additional 2,151 shares during the last quarter. Gagnon Securities LLC grew its position in shares of GoodRx by 9.9% in the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company's stock worth $325,000 after buying an additional 6,266 shares during the last quarter. Swiss National Bank grew its position in shares of GoodRx by 4.1% in the 4th quarter. Swiss National Bank now owns 161,400 shares of the company's stock worth $751,000 after buying an additional 6,400 shares during the last quarter. RPO LLC bought a new stake in shares of GoodRx in the 4th quarter worth approximately $52,000. Finally, Versor Investments LP bought a new stake in shares of GoodRx in the 4th quarter worth approximately $54,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Stock Performance

GoodRx stock traded down $0.05 during mid-day trading on Friday, reaching $3.96. 1,286,385 shares of the stock traded hands, compared to its average volume of 1,390,980. The stock has a market capitalization of $1.52 billion, a PE ratio of -132.00, a price-to-earnings-growth ratio of 2.46 and a beta of 1.24. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx Holdings, Inc. has a 12-month low of $3.68 and a 12-month high of $9.26. The business's 50-day moving average is $4.45 and its 200-day moving average is $4.66.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The business had revenue of $202.97 million during the quarter, compared to analysts' expectations of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The business's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.08 earnings per share. As a group, sell-side analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on GDRX shares. Wells Fargo & Company cut their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. UBS Group cut their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Truist Financial cut their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Finally, The Goldman Sachs Group cut their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $6.55.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.